Lanifibranor

CAS Number

• 927961-18-0

PubChem CID

• 68677842

DrugBank

• DB14801

ChemSpider

• 58828074

Lanifibranor

Molecular structure of lanifibranor
3D representation of a lanifibranor molecule
Identifiers
IUPAC name 4-[1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloroindol-2-yl]butanoic acid
CAS Number	927961-18-0
PubChem CID	68677842
DrugBank	DB14801
ChemSpider	58828074
UNII	28Q8AG0PYL
ChEMBL	ChEMBL4091374
ECHA InfoCard	100.218.645
Chemical and physical data
Formula	C19H15ClN2O4S2
Molar mass	434.91 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC2=C(C=C1S(=O)(=O)N3C4=C(C=C(C=C4)Cl)C=C3CCCC(=O)O)SC=N2
InChI InChI=1S/C19H15ClN2O4S2/c20-13-4-7-17-12(8-13)9-14(2-1-3-19(23)24)22(17)28(25,26)15-5-6-16-18(10-15)27-11-21-16/h4-11H,1-3H2,(H,23,24) Key:OQDQIFQRNZIEEJ-UHFFFAOYSA-N

Lanifibranor is a pan-peroxisome proliferator-activated receptor (PPAR) agonist and is the first medication that targets PPAR-alpha, PPAR-beta, and PPAR-gamma simultaneously.^[1][2][3] As of 2023, it is in a phase III trial for nonalcoholic steatohepatitis; its advantage over other drugs that are in phase III trials for the same condition is that it has shown improvements in both steatohepatitis and fibrosis.^[4]